1887

Journal of Medical Microbiology logo

Volume 72, Issue 2

Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against collected from clinical patients in PR China (2004–2021) Open Access

Abstract

. The increasing prevalence of multidrug-resistant (MDR) worldwide is a significant global public health concern. Ceftazidime/avibactam (CZA) has been considered a novel promising β-lactam/β-lactamase inhibitor combination antibiotic against difficult-to-treat isolates. Big data studies on CZA susceptibility against have been limited.

. Production of metallo-β-lactamases was the most prevalent resistance mechanism for against CZA.

. To assess the activity of CZA against strains and the relevant resistance mechanisms.

. One thousand three hundred and sixty-three isolates were collected from 2004 to 2021. Antimicrobial susceptibility testing was carried out for commonly used antipseudomonal drugs via the broth microdilution method. Polymerase chain reaction (PCR) or whole-genome sequencing were performed to analyse the most common carbapenemase genes. Molecular epidemiology was analysed by uploading the sequencing data to the Center for Genomic Epidemiology website.

. Antimicrobial susceptibility testing showed that CZA and lipopeptides are the most active antibiotics against isolates. PCR and genome sequencing revealed that the most prevalent resistance mechanism for against CZA was the production of metallo-β-lactamases. None of the mutations were found to be associated with avibactam resistance.

. Our findings revealed that CZA and lipopeptides are the most active antibiotics against isolates. The most prevalent resistance mechanism for against CZA was the production of metallo-β-lactamases, and none of the mutations were found to be associated with avibactam resistance.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antimicrobial susceptibility , carbapenemase , ceftazidime/avibactam and Pseudomonas aeruginosa
Funding
This study was supported by the:
  • the Natural Science Foundation of Zhejiang Province (Award LY20H200006)
    • Principle Award Recipient: YanyanHu
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001656
2023-02-08
2024-05-01
Loading full text...

Full text loading...

/deliver/fulltext/jmm/72/2/jmm001656.html?itemId=/content/journal/jmm/10.1099/jmm.0.001656&mimeType=html&fmt=ahah

References

  1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318–327 [View Article] [PubMed]
     [Google Scholar]
  2. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32:e00031-19 [View Article]
     [Google Scholar]
  3. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: second-generation β-Lactam/β-Lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234–241 [View Article]
     [Google Scholar]
  4. FDA Avycaz (ceftazidime and avibactam) for injection, for intravenous use: US prescribing information; 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf
  5. European Medicines Agency Zavicefta: summary of product characteristics; 2018Mar16 http://www.ema.europa.eu
  6. Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to novel β-Lactam-β-Lactamase inhibitor combinations: the “Price of Progress.”. Infect Dis Clin North Am 2020; 34:773–819 [View Article]
     [Google Scholar]
  7. Tu Y, Wang D, Zhu Y, Li J, Jiang Y et al. Emergence of a KPC-90 variant that confers resistance to Ceftazidime-Avibactam in an ST463 carbapenem-resistant Pseudomonas aeruginosa strain. Microbiol Spectr 2022; 10:e0186921 [View Article]
     [Google Scholar]
  8. Yang Y, Guo Y, Yin D, Zheng Y, Wu S et al. In Vitro activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and other comparators against clinical isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: results from China antimicrobial surveillance Network (CHINET) in 2018. Antimicrob Agents Chemother 2020; 65:e01726-20 [View Article]
     [Google Scholar]
  9. Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A et al. The ERACE-PA global surveillance program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro activity against a global collection of Carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2021; 40:2533–2541 [View Article]
     [Google Scholar]
  10. Karlowsky JA, Bouchillon SK, El Mahdy Kotb R, Mohamed N, Stone GG et al. In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18. JAC Antimicrob Resist 2021; 3:dlab067 [View Article]
     [Google Scholar]
  11. Wayne P. Performance Standards for Antimicrobial Susceptibility Testing; 31st Informational Supplement. CLSI Document M100-S31 Clinical and Laboratory Standards Institute; 2021
     [Google Scholar]
  12. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol 2012; 50:1355–1361 [View Article] [PubMed]
     [Google Scholar]
  13. Boolchandani M, D’Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet 2019; 20:356–370 [View Article] [PubMed]
     [Google Scholar]
  14. Hu Y, Liu C, Wang Q, Zeng Y, Sun Q et al. Emergence and expansion of a Carbapenem-resistant Pseudomonas aeruginosa clone are associated with plasmid-borne bla KPC-2 and virulence-related genes. mSystems 2021; 6:e00154-21 [View Article]
     [Google Scholar]
  15. Madeira F, Park YM, Lee J, Buso N, Gur T et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res 2019; 47:W636–W641 [View Article]
     [Google Scholar]
  16. Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 2014; 42:W320–4 [View Article]
     [Google Scholar]
  17. Pragasam AK, Raghanivedha M, Anandan S, Veeraraghavan B. Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile. Ann Clin Microbiol Antimicrob 2016; 15:12 [View Article] [PubMed]
     [Google Scholar]
  18. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 2002; 34:634–640 [View Article] [PubMed]
     [Google Scholar]
  19. Denisuik AJ, Karlowsky JA, Denisuik T, Nichols WW, Keating TA et al. In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals. Antimicrob Agents Chemother 2015; 59:3623–3626 [View Article] [PubMed]
     [Google Scholar]
  20. Nichols WW, de Jonge BLM, Kazmierczak KM, Karlowsky JA, Sahm DF. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 2016; 60:4743–4749 [View Article]
     [Google Scholar]
  21. Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 2015; 70:1650–1658 [View Article] [PubMed]
     [Google Scholar]
  22. Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2015; 59:1020–1029 [View Article] [PubMed]
     [Google Scholar]
  23. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S et al. Mutations in blaKPC-3 that confer Ceftazidime-Avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-Lactamases. Antimicrob Agents Chemother 2017; 61:e02534-16 [View Article]
     [Google Scholar]
  24. Zhu Y, Chen J, Shen H, Chen Z, Yang Q-W et al. Emergence of Ceftazidime- and Avibactam-resistant Klebsiella pneumoniae Carbapenemase-producing Pseudomonas aeruginosa in China. mSystems 2021; 6:e0078721 [View Article]
     [Google Scholar]
  25. Tu Y, Wang D, Zhu Y, Li J, Jiang Y et al. Emergence of a KPC-90 variant that confers resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-resistant Pseudomonas aeruginosa strain. Microbiol Spectr 2022; 10:e0186921 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001656
Loading
Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004–2021)
J. Med. Microbiol. 72, 001656 (2023); https://doi.org/10.1099/jmm.0.001656
/content/journal/jmm/10.1099/jmm.0.001656
/content/journal/jmm/10.1099/jmm.0.001656
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error